HER-2阳性治疗新方案 刚刚通过美国FDA 批准：Breast cancer research news: The FDA just approved Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) as a treatment for HER2-positive breast cancer. A loading dose can be administered in just eight minutes (compared to about 150 minutes for a loading dose of Perjeta and Herceptin by IV) and in a patient's home by a medical professional.